Ziprasidone therapy for post-traumatic stress disorder

Ziprasidone therapy for post-traumatic stress disorder

PDF

J Psychiatry Neurosci 2005;30(6):430-1

Zakaria Siddiqui, MD; William A. Marcil, MD; Subhash C. Bhatia, MD; Sriram Ramaswamy, MD; Frederick Petty, MD, PhD

Siddiqui — Department of Psychiatry, Douglas County CMHC; Marcil, Bhatia, Ramaswamy, Petty — Department of Psychiatry, Creighton University, Omaha, and Omaha Veterans Affairs Medical Center, Omaha, Neb.

Abstract

We describe the cases of 2 men with chronic combat-induced post-traumatic stress disorder (PTSD) who benefited from therapy with ziprasidone. They did not have active psychotic symptoms. Both the patients had a history of inadequate response to previous trials of different psychotropic agents. Ziprasidone was considered because of its broad-spectrum actions on various neurotransmitters. To our knowledge, this is the first published report of the usefulness of ziprasidone in the pharmacotherapy of PTSD, although atypical antipsychotic agents (e.g., olanzapine, quetiapine and risperidone) have been reported to be beneficial in the treatment of this condition.

Résumé

Nous décrivons les cas de deux hommes atteints d’un syndrome de stress post-traumatique (SSPT) chronique attribuable au combat et qui ont bénéficié d’une thérapie à la ziprasidone. Ils n’avaient pas de symptômes psychotiques actifs. Les patients avaient déjà répondu inadéquatement à des essais antérieurs de divers agents psychotropes. On a envisagé la ziprasidone en raison du large spectre de ses effets sur divers neurotransmetteurs. Il s’agit, sauf erreur, du premier rapport publié sur l’utilité de la ziprasidone dans la pharmacothérapie du SSPT, même si l’on a déjà signalé que des antipsychotiques atypiques (p. ex., olanzapine, quétiapine et rispéridone) avaient un effet bénéfique dans le traitement de cette affection.


Medical subject headings: stress disorders, post-traumatic; ziprasidone.

Submitted Feb. 23, 2005; Revised July 13, 2005; Accepted Aug. 16, 2005

Competing interests: None declared for Drs. Siddiqui, Marcil and Ramaswamy. Dr. Bhatia is on the speakers’ bureau for Janssen, AstraZeneca, Bristol Myers-Squibb, Shire and Pfizer and has received travel assistance to attend advisory board meetings. Dr. Petty owns stock in Pfizer, has been a paid consultant for Bristol Myers-Squibb and AstraZeneca, has received honoraria from Pfizer, Bristol Myers-Squibb and AstraZeneca, has received speaker fees from Lilly, Bristol Myers-Squibb, Janssen and Abbot, and has received travel asistance from Ortho McNeil.

Contributors: Drs. Siddiqui, Ramaswamy and Petty conceived and designed the study. Dr. Siddiqui collected the data. Drs. Siddiqui, Marcil, Bhatia and Petty analyzed the data. Drs. Siddiqui and Petty wrote the article. Drs. Marcil, Bhatia, Ramaswamy and Petty critically reviewed the article. All authors gave final approval for the article to be published.

Correspondence to: Dr. Zakaria Siddiqui, Department of Psychiatry, Douglas County CMHC, 4102 Woolworth St., Omaha NE 68105; fax 402 444-6338; zsiddiqui@co.douglas.ne.us